Published in Arthritis Rheum on June 01, 1989
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest (1998) 1.79
Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58
Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum (2008) 1.43
Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child (2003) 1.07
Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol Int (2005) 0.82
Identification and characterization of the direct interaction between methotrexate (MTX) and high-mobility group box 1 (HMGB1) protein. PLoS One (2013) 0.81
Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan. Mod Rheumatol (2008) 0.79
The adolescent with rheumatic disease. Arch Dis Child (1997) 0.76
Phase II trial of methotrexate in myasthenia gravis. Ann N Y Acad Sci (2012) 0.75
Methotrexate therapy in systemic-onset juvenile rheumatoid arthritis in Saudi Arabia: a retrospective analysis. Clin Rheumatol (1998) 0.75
Properties of highly purified human properdin. J Immunol (1968) 3.96
Time-motion study of practicing pediatricians. Pediatrics (1966) 3.32
Job's Syndrome. Recurrent, "cold", staphylococcal abscesses. Lancet (1966) 3.27
Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol (1996) 2.56
Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia (2000) 2.48
Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum (2012) 2.37
Immune response after splenectomy. Lancet (1978) 2.31
Significance of bacterial variants in urine of patients with chronic bacteriuria. J Clin Invest (1965) 2.18
Intrathecal leucovorin after intrathecal methotrexate overdose. J Pediatr Hematol Oncol (1996) 2.06
Hepatic involvement in juvenile rheumatoid arthritis. J Pediatr (1970) 2.05
The clinical pharmacology of methotrexate: new applications of an old drug. Cancer (1978) 2.05
Severe recurrent bacterial infections associated with defective adherence and chemotaxis in two patients with neutrophils deficient in a cell-associated glycoprotein. J Pediatr (1982) 2.03
Telephone assessment of illness by practicing pediatricians. J Pediatr (1976) 1.93
Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics (2000) 1.91
The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood (1980) 1.91
Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol (1997) 1.87
Activity of colistin against Pseudomonas aeruginosa: inhibition by calcium. J Infect Dis (1971) 1.82
Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases. J Clin Invest (1971) 1.76
The development of hemostasis in the human fetus and newborn infant. J Pediatr (1971) 1.75
The primary immunodeficiencies (1). N Engl J Med (1984) 1.74
The primary immunodeficiencies. N Engl J Med (1995) 1.65
Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep (1981) 1.62
Defective humoral immunity in pediatric acquired immune deficiency syndrome. J Pediatr (1985) 1.61
Defect in neutrophil granulocyte chemotaxis in Job's syndrome of recurrent "cold" staphylococcal abscesses. Lancet (1974) 1.56
Linkage between the gene (or genes) controlling synthesis of the fourth component of complement and the major histocompatibility complex. N Engl J Med (1977) 1.55
The syndrome of dysuria and hematuria in pediatric urinary reconstruction with stomach. J Urol (1993) 1.51
Kinetics of the transformation of Gram-negative rods to spheroplasts and ghosts by serum. J Immunol (1966) 1.51
Mapping of the X-linked agammaglobulinemia locus by use of restriction fragment-length polymorphism. J Clin Invest (1986) 1.49
Joint distribution at presentation in children with pauciarticular arthritis. J Pediatr (1999) 1.49
Kienbock's disease--avascular necrosis of the carpal lunate bone--in a 7-year-old girl with dermatomyositis. Clin Pediatr (Phila) (1994) 1.47
Juvenile rheumatoid arthritis: a review. Pediatrics (1972) 1.46
Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev (1977) 1.46
Absence of erythrocyte adenosine deaminase associated with severe combined immunodeficiency. J Pediatr (1974) 1.46
The management of cancer in the older adolescent. Eur J Cancer (2003) 1.45
The primary immunodeficiencies. (2). N Engl J Med (1984) 1.43
Immune response of a patient with deficiency of the fourth component of complement and systemic lupus erythematosus. N Engl J Med (1979) 1.41
Neuroblastoma screening in the United States: results of the Texas Outreach Program for neuroblastoma screening. Cancer (1998) 1.40
Accidental intramuscular vincristine: lack of untoward effects and recommendations for management. Med Pediatr Oncol (1997) 1.39
Craniospinal irradiation for acute lymphoblastic leukemia with central nervous system disease at diagnosis: a report from the Children's Cancer Group. Int J Radiat Oncol Biol Phys (1996) 1.39
Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr (1998) 1.39
Hypergammaglobulinaemia, antibody deficiency, autoimmune haemolytic anaemia, and nephritis in an infant with a familial lymphopenic immune defect. Lancet (1966) 1.38
Parent reaction to the concept of pediatric assistants. Pediatrics (1969) 1.34
Intravenous immunoglobulin home treatment for patients with primary immunodeficiency diseases. Lancet (1986) 1.31
Acute lymphoblastic leukemia in infants less than one year of age: a cumulative experience of the Children's Cancer Study Group. J Clin Oncol (1985) 1.31
Classification of primary immunodeficiencies. N Engl J Med (1973) 1.28
Hypocalcemia, hyperphosphatemia, and dehydration following a single hypertonic phosphate enema. J Pediatr (1977) 1.28
Aspirin and acetaminophen use by pregnant women and subsequent child IQ and attention decrements. Teratology (1987) 1.24
Pharmacokinetics of oral methotrexate in children. Cancer Res (1983) 1.24
Paradoxical synergism and antagonism between serum and the antibacterial activity of colistin. J Infect Dis (1971) 1.23
Antibiotics for Pseudomonas aeruginosa sepis: inadequate proof of efficacy. J Infect Dis (1971) 1.21
Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med (1973) 1.19
Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol (1993) 1.17
The role of complement in the induction of antibody responses. Clin Exp Immunol (1983) 1.16
Adenosine-deaminase deficiency and severe combined immunodeficiency syndrome. Lancet (1973) 1.16
Conduct of phase I trials in children with cancer. J Clin Oncol (1998) 1.16
Primate model for long-term study of intraventricularly or intrathecally administered drugs and intracranial pressure. Science (1977) 1.15
The recognition and classification of immunodeficiency diseases with bacteriophage phiChi 174. Birth Defects Orig Artic Ser (1975) 1.15
The effect of initial management of hyperleukocytosis on early complications and outcome of children with acute lymphoblastic leukemia. J Clin Oncol (1988) 1.13
Successful treatment of echovirus meningoencephalitis and myositis-fasciitis with intravenous immune globulin therapy in a patient with X-linked agammaglobulinemia. N Engl J Med (1981) 1.13
Studies on the detection of adverse drug reactions in the newborn. II. The effects of prenatal aspirin on newborn hemostasis. JAMA (1970) 1.12
Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol (1990) 1.10
Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med (1984) 1.10
Autoimmunity in the relatives of patients with immunodeficiency diseases. Clin Exp Immunol (1977) 1.10
The role of penicillin-induced bacterial variants in experimental pyelonephritis. J Exp Med (1967) 1.10
Juvenile rheumatoid arthritis persisting inot adulthood. Am J Med (1968) 1.10
Bacterial L-forms in relapsing urinary-tract infection. Lancet (1967) 1.08
Defective antibody response to bacteriophage phichi 174 in Down syndrome. J Pediatr (1975) 1.08
Treatment of neonatal lupus: case report and review of the literature. J Rheumatol (1993) 1.08
Combined immunodeficiency and reticuloendotheliosis with eosinophilia. J Pediatr (1974) 1.08
Perinatal infection with human immunodeficiency virus. Specific antibody responses by the neonate. N Engl J Med (1987) 1.07
Spinal descent of cerebrospinal fluid in man. Neurology (1976) 1.07
Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol (1987) 1.06
Irradiation, methotrexate toxicity, and the treatment of meningeal leukaemia. Lancet (1973) 1.06
The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med (1988) 1.06
Antibody studies in hypogammaglobulinemia. J Clin Invest (1966) 1.04
Histocompatibility antigens in childhood-onset arthritis. J Pediatr (1976) 1.04
Methotrexate pneumonitis induced by intrathecal methotrexate therapy: a case report with pharmacokinetic data. Cancer (1976) 1.03
Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol (1985) 1.03
Induction of T-lymphocyte differentiation by thymic epithelial cell monolayers. Clin Immunol Immunopathol (1978) 1.01
Intravenous immunoglobulin: a review. Immunodefic Rev (1989) 1.01
Lysozyme and serum bactericidal action. Nature (1966) 1.01
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res (1998) 0.99
Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet (1983) 0.99
Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. N Engl J Med (1980) 0.98
Ankylosing spondylitis with childhood onset. J Pediatr (1969) 0.98
Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group. Med Pediatr Oncol (1996) 0.97
Arthritis and immunodeficiency. J Pediatr (1972) 0.96
Prognostic implications of blast cell morphology in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. Cancer Treat Rep (1985) 0.95
Immunologic responses in the axolotl, Siredon mexicanum. J Immunol (1967) 0.95
Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol (1983) 0.95
Epstein-Barr virus-induced lymphoblastoid cell lines derived from the peripheral blood of patients with X-linked agammaglobulinemia can secrete IgM. J Clin Immunol (1984) 0.94
A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum (1994) 0.94
Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep (1977) 0.94
A primate model for study of methotrexate pharmacokinetics in the central nervous system. Cancer Res (1977) 0.93
Episcleritis in childhood. Ophthalmology (1999) 0.93
Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort. Lupus (2010) 0.92
Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol (1989) 0.92
"Concentration x time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood (1978) 0.92